Baldwin Wealth Partners LLC MA Has $517,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Baldwin Wealth Partners LLC MA lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 43.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,988 shares of the medical research company’s stock after selling 5,300 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Edwards Lifesciences were worth $517,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Bowman & Co S.C. boosted its holdings in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Mount Yale Investment Advisors LLC lifted its position in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after buying an additional 162 shares during the last quarter. JFS Wealth Advisors LLC boosted its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares in the last quarter. Seascape Capital Management increased its holdings in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after acquiring an additional 174 shares during the last quarter. Finally, Cooper Financial Group raised its stake in shares of Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after acquiring an additional 175 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EW shares. The Goldman Sachs Group increased their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Barclays raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Stifel Nicolaus raised their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Stock Down 0.2 %

Shares of NYSE:EW opened at $68.88 on Monday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $40.63 billion, a P/E ratio of 9.94, a P/E/G ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company’s 50-day moving average price is $72.33 and its two-hundred day moving average price is $70.36.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.